Singapore's HSA to vet Sinovac vaccine before public roll-out

Singapore

A CORONAVIRUS vaccine developed by China's Sinovac Biotech will have to go through regulatory scrutiny and authorisation by Singapore's Health Sciences Authority (HSA) before it can be rolled out to the public, Health Minister Gan Kim Yong said on Wednesday.

This update follows the release of data on a Brazilian trial on Tuesday, which showed that the Sinovac vaccine was just 50.4 per cent effective at preventing symptomatic infections. This barely meets the threshold for regulatory approval and is well below the rate announced last week.